Pharmaceutical group ยท Switzerland
Octapharma
A group of 29 companies with 281 medicines in 10 countries.
Loading your pageโฆ
Loading your pageโฆ
Pharmaceutical group ยท Switzerland
A group of 29 companies with 281 medicines in 10 countries.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
29 companies in 14 countries
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine of every company in the group, current ones first.
1โ25 of 281
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| ALBUNORMSoluzione per infusione | Albumin | Italy | Authorised | |
| ALBUNORM 20%, 200 g/l SOLUCION PARA PERFUSION200 g ยท Soluciรณn para perfusiรณn | Albumin | Spain | Marketed | 2009 |
| Albunorm 20%, oplossing voor infusieOplossing voor infusie | Albumin | Netherlands | Authorised | 2009 |
| ALBUNORM 5%, 50 g/l SOLUCION PARA PERFUSION50 g ยท Soluciรณn para perfusiรณn | Albumin | Spain | Marketed | 2009 |
| Albunorm 5%, oplossing voor infusieOplossing voor infusie | Albumin | Netherlands | Authorised | 2009 |
| ANTERNATYPolvere e solvente per soluzione per infusione endovenosa | Antithrombin iii | Italy | Authorised | |
| ATENATIVPolvere e solvente per soluzione per infusione endovenosa | Antithrombin iii | Italy | Authorised | |
| ATENATIV 1000 UI, POLVO Y DISOLVENTE PARA SOLUCION PARA PERFUSION1000 ui ยท Polvo y disolvente para soluciรณn para perfusiรณn | Antitrombina iii humana | Spain | Marketed | 1990 |
| Atenativ 50 IE/ml poeder en oplosmiddel voor oplossing voor infusiePoeder en oplosmiddel voor oplossing voor infusie | Antithrombin iii | Netherlands | Authorised | 2026 |
| Atenativ 50 IU/ml praลกak i otapalo za otopinu za infuzijuPraลกak i otapalo za otopinu za infuziju | Antithrombin iii | Croatia | Not marketed | 2026 |
| ATENATIV 500 U.I. POLVO Y DISOLVENTE PARA SOLUCION PARA PERFUSION500 ui ยท Polvo y disolvente para soluciรณn para perfusiรณn | Antitrombina iii humana | Spain | Marketed | 1990 |
| ATenativ, poeder voor infusievloeistof 500 IE en 1000 IEPoeder voor oplossing voor infusie | Antithrombin iii | Netherlands | Authorised | 1996 |
| Balfaxar1000iu ยท For Injection | Prothrombin complex concentrate, human | United States | Marketed | 2023 |
| Balfaxar500iu ยท For Injection | Prothrombin complex concentrate, human | United States | Marketed | 2023 |
| CUTAQUIG2 g / 12 ml ยท Solution | Immunoglobulin | Canada | Not marketed | 2018 |
| CUTAQUIG1.65 g / 10 ml ยท Solution | Immunoglobulin | Canada | Authorised | |
| Cutaquig1g/6ml ยท Solution | Immune globulin subcutaneous | United States | Marketed | 2018 |
| CUTAQUIGSoluzione iniettabile | Immunoglobulina umana normale | Italy | Authorised | |
| Cutaquig8g/48ml ยท Solution | Immune globulin subcutaneous | United States | Marketed | 2018 |
| Cutaquig3.3g/20 ml ยท Solution | Immune globulin subcutaneous | United States | Marketed | 2018 |
| CUTAQUIG3.3 g / 20 ml ยท Solution | Immunoglobulin | Canada | Authorised | |
| CUTAQUIG4 g / 24 ml ยท Solution | Immunoglobulin | Canada | Not marketed | 2018 |
| Cutaquig1.65g/10 ml ยท Solution | Immune globulin subcutaneous | United States | Marketed | 2018 |
| Cutaquig2g/12ml ยท Solution | Immune globulin subcutaneous | United States | Marketed | 2018 |
| Cutaquig4g/24ml ยท Solution | Immune globulin subcutaneous | United States | Marketed | 2018 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Saudi Arabia | 58 | 58 | 0 | CompaniesAll medicines |
| Spain | 47 | 33 | 14 | CompaniesAll medicines |
| United States | 43 | 43 | 0 | CompaniesAll medicines |
| Netherlands | 37 | 37 | 0 | CompaniesAll medicines |
| Romania | 33 | 0 | 33 | CompaniesAll medicines |
| Canada | 26 | 26 | 0 |
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Companies are grouped by Prognia from the names regulators publish; not an official corporate structure.
Source: European Medicines Agency (EPAR data).
Licence: EMA reuse policy (source acknowledgement required)
Fuente de la informaciรณn: AEMPS (CIMA).
Licence: AEMPS open data reuse with attribution
Source: BDPM (ANSM, HAS, UNCAM).
Licence: Licence Ouverte v1.0
ANVISA / CMED, consumer price table; embedded source date 2026-07-21 and retrieval date
Licence: Other (Public Domain)
Anvisa published factual open-data CSV https://dados.anvisa.gov.br/dados/CONSULTAS/PRODUTOS/TA_CONSULTA_MEDICAMENTOS.CSV, HTTP version Mon, 12 Oct 2026 11:45:25 GMT; acquired 12 October 2026; original source states and timestamps retained.
Licence: Brazil federal factual open data, consolidated Decreto 8777/2016 article 4; attribution and third-party exceptions
Anvisa, official medicine/API manufacturer factual export, HTTP source version Fri, 09 Oct 2026 08:21:54 GMT, acquired 2026-10-09; exact unmodified native identifiers and fields preserved.
Licence: Brazil federal factual open-data reuse; Decreto 8777/2016 consolidated article 4 and third-party exceptions
| CompaniesAll medicines |
| Italy | 16 | 16 | 0 | CompaniesAll medicines |
|---|
| Brazil | 14 | 9 | 5 | CompaniesAll medicines |
|---|
| Croatia | 5 | 5 | 0 | CompaniesAll medicines |
|---|
| European Union (EMA) | 2 | 2 | 0 | CompaniesAll medicines |
|---|
Also in the registers of France, Serbia, United Kingdom
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Fuente de la informaciรณn: Agencia Espaรฑola de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Fuente de la informaciรณn: Agencia Espaรฑola de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
BDPM / ANSM, HAS and UNCAM; original URLs and each update date retained
Licence: BDPM exact Licence Ouverte v1.0 (October 2011)
INSEE (www.insee.fr), via DINUM API Recherche dโentreprises; include original record update date and retrieval date
Licence: Licence Ouverte / Open Licence
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 1 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:47.757811+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 2 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:48.423930+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
HALMED, Baza lijekova, source export 08.10.2026., acquired 2026-10-08; factual structured adaptation; Otvorena dozvola RH, NN 67/2017.
Licence: Otvorena dozvola RH
Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_A_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:41 GMT; acquired 2026-10-13T17:21:06.055244+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_H_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:40 GMT; acquired 2026-10-13T17:21:06.034935+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
Agenzia Italiana del Farmaco (AIFA); https://drive.aifa.gov.it/farmaci/confezioni_fornitura.csv; HTTP Last-Modified Mon, 12 Oct 2026 23:02:44 GMT; acquired 2026-10-13T17:21:16.224007+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
College ter Beoordeling van Geneesmiddelen, Geneesmiddeleninformatiebank metadata, source update 07-10-2026; downloaded 08-10-2026; factual adaptation.
Licence: Conditional noncreative administrative factual metadata; no dataset-wide CC0 claim
Contains data under the Norwegian licence for Open Government data (NLOD) distributed by Brรธnnรธysundregistrene. https://data.norge.no/nlod/en/2.0; original API URLs, retrieval dates and locators. Selected and normalized by Prognia; fractional JSON numbers preserved as labelled exact decimal strings.
Licence: Norwegian Licence for Open Government Data
Ministerul Sฤnฤtฤศii, Catalogul public naลฃional al preลฃurilor, 18 iunie 2021, downloaded 2026-10-08 from data.gov.ro; CC BY 4.0; structured factual adaptation, code whitespace trimmed only where explicitly recorded.
Licence: Creative Commons Attribution 4.0 International (CC BY 4.0)
ALIMS, Registar humanih lekova, source 08.10.2026 02:00, downloaded 2026-10-08, https://data.gov.rs/sr/datasets/lekovi-za-upotrebu-u-khumanoj-meditsini/; structured factual adaptation; Serbian Open Data Licence.
Licence: Serbian Open Data Licence (sodl)
Saudi Food and Drug Authority (SFDA), foreign human medicine open-data listing, source scope 2023, retrieved 11 October 2026 UTC; exact original file and response modification date retained.
Licence: Exact SFDA open-data section explicitly offers freely usable named human medicine workbooks; factual-data scope only
FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.
Licence: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions
Report an error or request removalCorrections from the company itself are welcome.
Well-known pharmaceutical groups, each with all its companies.
Ranked by their number of medicines.